Objective:To study the clinical effect of Qumei trimetazidine in treatment of ischemic heart disease. Method:randomly selected from the patients with ischemic heart disease in our hospital in 2010 October ~2013 year in October admit ed in 80 cases studied, on al subjects were treated with furosemide, cardiotonic, and angiotensin converting enzyme inhibitors and beta blockers and other drugs for treatment, combined with trimetazidine. Study of EF were observed before and after treatment (ejection fraction) and LVS (left ventricular end systolic diameter), and FS (shortening) and LVD (left ventricular end diastolic diameter) and adverse reaction conditions and treatment effect.Results:the course of treatment, no serious adverse reactions were seen in al patients;after treatment, measurement in patients with EF (ejection fraction) and LVS (left ventricular end systolic diameter (FS) and fractional shortening (LVD) and left ventricular end diastolic diameter) were significantly increased compared with before therapy, P<0.01;the total effective rate was 95%. Conclusion:for the treatment of ischemic heart disease can get bet er treatment effect by Qumei trimetazidine clinical.
NETL
NSTL
万方数据
